The cost of a Reclast (zoledronic acid) infusion in 2025 is not yet publicly available, as pricing is typically set closer to the year of service and can vary significantly. Factors influencing the cost include the healthcare provider, geographic location, insurance coverage, and whether the infusion is administered in a hospital outpatient setting or a physician's office [1].
How much does Reclast cost with insurance?
Insurance coverage for Reclast infusions can substantially reduce out-of-pocket expenses. Many insurance plans, including Medicare Part D, cover Reclast for approved indications such as osteoporosis and Paget's disease of bone [2]. However, patients may still be responsible for copayments, deductibles, or coinsurance, which will vary based on the specific insurance plan [1]. It is advisable for patients to contact their insurance provider directly to understand their benefits and potential costs.
What is the average out-of-pocket cost for Reclast?
Without insurance, the average out-of-pocket cost for a single Reclast infusion can range from approximately $300 to over $1,000 [3]. This price reflects the cost of the drug itself and the administration fee. These figures are estimates and can fluctuate based on market conditions and provider pricing.
When does Reclast patent expire?
The primary patents for Reclast (zoledronic acid) have expired, allowing for the potential development and marketing of generic versions. For instance, some sources indicate that patent exclusivity for Reclast has ended [4]. The expiration of these patents can lead to increased competition from generic manufacturers, potentially impacting overall drug costs.
Are there generic versions of Reclast available?
Yes, generic versions of zoledronic acid, the active ingredient in Reclast, are available. The availability of generics can offer a more affordable alternative to the brand-name drug [4]. The pricing of these generic alternatives is determined by individual manufacturers and market competition.
How does Reclast work to treat osteoporosis?
Reclast is a bisphosphonate medication that works by slowing down bone loss. It inhibits osteoclasts, the cells responsible for breaking down bone tissue. By reducing bone resorption, Reclast helps to increase bone density and reduce the risk of fractures, particularly in individuals with osteoporosis [5].
What are the alternatives to Reclast infusions?
Alternative treatments for osteoporosis include other bisphosphonates (oral or intravenous), denosumab (Prolia), teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity) [6]. The choice of treatment depends on individual patient factors, including the severity of osteoporosis, medical history, and potential side effects.
What are the risks associated with Reclast?
Potential risks and side effects of Reclast infusions include flu-like symptoms, fever, chills, muscle or joint pain, and kidney problems [5]. More serious, though less common, risks include osteonecrosis of the jaw (ONJ) and atypical femur fractures [7]. Patients should discuss these risks thoroughly with their healthcare provider before starting treatment.
What is the recommended dosage frequency for Reclast?
For the treatment of osteoporosis in postmenopausal women and men, Reclast is typically administered as a single intravenous infusion once a year [5]. For other indications, such as Paget's disease, the dosing frequency may differ.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/reclast
[3] https://www.medicalnewstoday.com/articles/325856
[4] https://www.goodrx.com/zoledronic-acid
[5] https://www.mayoclinic.org/drugs-supplements/zoledronic-acid-intravenous-route/proper-use/drg-20064080
[6] https://www.uptodate.com/contents/overview-of-the-management-of-osteoporosis-in-postmenopausal-women
[7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-new-information-about-bisphosphonates-used-treat-osteoporosis